GENF vs. IMM, IXI, SNG, BVX, OBD, CIZ, APTA, HEMO, FAB, and EVG
Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include ImmuPharma (IMM), IXICO (IXI), Synairgen (SNG), BiVictriX Therapeutics (BVX), Oxford BioDynamics (OBD), Cizzle Biotechnology (CIZ), Aptamer Group (APTA), Hemogenyx Pharmaceuticals (HEMO), Fusion Antibodies (FAB), and Evgen Pharma (EVG). These companies are all part of the "biotechnology" industry.
Genflow Biosciences vs. Its Competitors
Genflow Biosciences (LON:GENF) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.
Genflow Biosciences has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
ImmuPharma received 266 more outperform votes than Genflow Biosciences when rated by MarketBeat users.
In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.
9.2% of Genflow Biosciences shares are held by institutional investors. Comparatively, 17.4% of ImmuPharma shares are held by institutional investors. 64.2% of Genflow Biosciences shares are held by company insiders. Comparatively, 48.3% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
ImmuPharma has a net margin of 3,519.56% compared to Genflow Biosciences' net margin of 778.46%. ImmuPharma's return on equity of -131.41% beat Genflow Biosciences' return on equity.
Genflow Biosciences has higher earnings, but lower revenue than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Genflow Biosciences and ImmuPharma tied by winning 6 of the 12 factors compared between the two stocks.
Get Genflow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genflow Biosciences Competitors List
Related Companies and Tools
This page (LON:GENF) was last updated on 6/14/2025 by MarketBeat.com Staff
Buy GENF Stock Free GENF Stock Alerts